8亿港元!和铂医药获大药企注资

药智网
25 Mar

近日,和铂医药宣布与AstraZeneca Holdings(阿斯利康)达成战略合作,同时完成股份认购协议的签署。此次合作不仅为和铂医药注入超1.05亿美元资金,更标志着其创新抗体疗法研发能力获得国际认可,有望加速管线商业化进程。图片来源:摄图网根据和铂医药新闻稿,此次战略合作内容涵盖基于和铂医药专有的Harbour Mice全人源抗体技术平台在多治疗领域的多项目授权许可协议。阿斯利康将获得两项...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10